There is no excerpt because this is a protected post.
We track the Biotech iShares each week, and here is the up to the minute view of a constructive situation breaking to a bullish one.
A look at the general Healthcare ETF (XLV), which includes BioPharma, Devices/Equipment and Services shows it easing below the trend line. IHI is at lateral
The Biotech iShares IBB shot up on some beneficial talk out of the Trump administration and, in my opinion, on beneficial Treasury yield dynamics. So
Yesterday we got the surge and then the ease into the close. Today? Err… The weekly now targets 350, barring a harsh reversal over the
It’s been a long time coming for the Biotech sector that has for me included some stops and starts in AMGN, GILD and IBB itself.
While I currently work with all sorts of macro-fundamental indicators and inter-market ratio charts, I started out just loving the act of creating and analyzing
Sending to the entire subscriber base since this works as a macro-related update as well. First, a long-term chart we have reviewed on occasion showing
This update on the Biotech iShares works as both an NFTRH+ update and a regular update. For the purposes of our regular updating, a breakout
Biotech, an important momentum leader to the stock market, is going to need to think about finding support soon lest this become something more than
Yesterday we noted the Biotechs had lower to go, and lower they went. Typical of today’s momo driven markets IBB took the express elevator right
I would be careful here on Biotech. The reversal candle signaled a fallout from a mini blow off. The level to which IBB became over
 post unlocked to give public readers an idea of how NFTRH manages the entirety of the market (not just special interests like precious metals,